Biote Corp. · NASDAQ:BTMD
Biote — Investor Presentation (April 2026)
26 slides from Biote's investor presentation, Apr 3, 2026
Slide 1: Transforming Healthy Aging
Exhibit 99.1 Transforming Healthy Aging
Slide 2: Forward-Looking Statements
2 Transforming Healthy Aging Forward-Looking Statements Forward-Looking Statements Certain statements in this Presentation may be considered “forward-looking statements” within the meaning of the provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statem
Slide 3: Looking Forward: Our Vision
3 Transforming Healthy Aging Looking Forward Biote offers an Our Vision evidence-based, To be a part of individualized, and everyone’s routine comprehensive healthcare as approach to they age healthcare
Slide 4: Biote by the Numbers
4 Transforming Healthy Aging 1 Biote by the Numbers The Established Leader in Hormone Optimization $192.2M > 9,200 2025 Revenue Biote-Certified Practitioners 2 ~6M $53.5M Procedures 2025 Adj. EBITDA Performed 2 27.8% ~400,000 2025 Adj. EBITDA Active Patients Margin 1. All information as of December
Slide 5: Investment Highlights
5 Transforming Healthy Aging Investment Highlights Proprietary Trusted Leader in Large & Growing Growing, Profitable Technology, Hormone Addressable & Capital-light Clinical, Education Optimization Markets Business Model & Training Platform Becoming the Leading Single-Source Provider of Evidence-Bas
Slide 6: Why Hormone Optimization
6 Transforming Healthy Aging Why Hormone Optimization ~47M Women Hormone Deficiency Impacts Quality of Life and affected with menopausal Heightens Risk of Chronic Disease (8) symptoms Common Hormone deficiency (1) symptoms: increases risk of: (2)(3) • Low energy • Heart disease ~20M Men (4)(5) • Ins
Slide 7: Biote: A Better Solution for Practitioners & Patients
7 Transforming Healthy Aging Biote: A Better Solution for Practitioners & Patients 1 Network of >9,200 certified practitioners • OB/GYN Biote-certified practitioners customize • Family Practice/Internal Medicine treatment therapies based on our • Urology proprietary algorithms to meet each • Functio
Slide 8: A More Proactive and Holistic Approach to Healthcare
8 Transforming Healthy Aging A More Proactive and Holistic Approach to Healthcare Practitioners Seek: § Single-source technology platform § Therapies to address common health conditions § Revenue opportunities that enhance clinic economics Patients Seek: § Ease and convenience from a single provider
Slide 9: Hormone Optimization Leader to Therapeutic Wellness Leader
9 Biote 2012-2023 Hormone Optimization Leader Biote 2024-2026 Becoming a Therapeutic Wellness Leader Evidence-Based Tech-Enabled + Therapeutics Platform Expansive Portfolio DRIVEN by Comprehensive of Products BEST-IN-CLASS Biote personalized ü People ü Weight Loss/ BioteRx Body Comp Biote wellness s
Slide 10: Large & Growing Markets
10 Transforming Healthy Aging Large & Growing Markets 82% of US Consumers Consider US Therapeutic Wellness a Top or Important Wellness (10) Priority in their Everyday Lives $400B+ § Growing patient interest in personal health & wellness (10) 5-10% CAGR § Patient desire for evidence-based results Hor
Slide 11: Significant Geographic & Practitioner Expansion Opportunity
11 Transforming Healthy Aging Significant Geographic & Practitioner 1 Expansion Opportunity Practitioner Opportunity 2 Building on our success in our core states 260,000 US Practitioners with to efficiently scale our presence Relevant Specialties § Tech-enabled, franchise- like highly-scalable busin
Slide 12: Nutraceuticals Complement Our Hormone Therapy Offerings
12 Transforming Healthy Aging Nutraceuticals Complement Our Hormone Therapy Offerings § Biote-branded dietary supplements and cosmeceuticals § Complementary to procedures performed by Biote-certified practitioners § Nutraceuticals strengthen the patient connection to Biote and enhance practitioner e
Slide 13: BioteRx: New Therapeutic Wellness Offerings
13 Transforming Healthy Aging BioteRx: New Therapeutic Wellness Offerings from a Trusted Network of Providers Wellness Categories Hormone Optimization Weight Loss/ Thyroid Body Composition Health Sexual Preventive Health Wellness Hair Loss/ Aesthetic Dermatology
Slide 14: Our Scalable & Proprietary Platform Drives Clinic Success
14 Transforming Healthy Aging Our Scalable & Proprietary Platform Drives Clinic Success + + + + = The Biote Method Clinical Didactic & Access to Practice Practice Proprietary Decision High Quality Training Clinical Retention Practice Support Certification Products and Support Management Software Tra
Slide 15: Commitment to Research
15 Commitment to Research Transforming Healthy Aging § The Aging Male Leadership in Education, § European Journal of Breast Health § Therapeutic Advances in Endocrinology and Metabolism Training & Research (14) Breast Cancer Study § Testosterone and/or Testosterone/Estradiol delivered subcutaneously
Slide 16: 2025 Financial Results & 2026 Outlook
16 Transforming Healthy Aging 2025 Financial Results & 2026 Outlook 2025 Results 2026 Guidance § $192.2 Revenue § Revenue: Above $190M 1 § $53.5M Adj. EBITDA . 1 § Adj EBITDA 1 § 27.8% Adj. EBITDA Margin Above $38M § >9,200 Practitioners 1. Adjusted EBITDA and Adjusted EBITDA Margin are non-GAAP fin
Slide 17: Capital Allocation Priorities
17 Transforming Healthy Aging Capital Allocation Priorities Organic Drive growth, gain efficiency and expand capabilities Investments Company repurchased approximately 5.5M shares of its Class V voting stock Share for $25.1M Repurchases Company executed an amendment to the settlement agreement repur
Slide 18: Strengthened Capabilities
18 Transforming Healthy Aging Strengthened Capabilities ▪ Strategic acquisition strengthens control over our supply chain and enhances our efficiency ▪ Deep expertise in 503B manufacturing ▪ Enables longer-term development of innovative wellness therapeutics ▪ Vertical integration of manufacturing p
Slide 19: Our 2026 Priorities
19 Transforming Healthy Aging Our 2026 Priorities ▪ Strengthen our efforts to maximize the value from our top-tier providers ▪ Fully leverage the capabilities of our enhanced clinical decision support software ▪ Continue to develop more high-value and differentiated offerings for our practitioners a
Slide 20: Key Takeaways
20 Transforming Healthy Aging Key Takeaways ▪ Leveraging our leadership in hormone optimization to capture the significant growth opportunity in therapeutic wellness ▪ Our addressable market is substantial, and that we have only just begun to tap into the geographic expansion opportunity in front of
Slide 21: Thank You
21 Thank You
Slide 22: Appendix A
22 Appendix A
Slide 23: Reconciliation of Adjusted EBITDA to Net Income
23 Reconciliation of Adjusted EBITDA to Net (Loss) Income Year Ended December 31, (in thousands) 2025 2024 Net income $ 3 1,597 $ 4 6 (1) 10,961 1 1,001 Interest expense, net Income tax (benefit) expense 5 ,987 9 70 (2) 3,670 3 ,574 Depreciation and amortization (3) 8,921 8 ,735 Share-based compensa
Slide 24: Reconciliation of Adjusted EBITDA to Net Income (Footnotes)
24 Reconciliation of Adjusted EBITDA to Net (Loss) Income (1) Represents cash and non-cash interest on our debt obligations, commitment fees for our unused Revolving Loans, net of interest income earned on our money market account. For the years ended December 31, 2025 and 2024, interest expense, ne
Slide 25: Appendix B
25 Appendix B
Slide 26: Sources
26 Sources (1) Cardozo et al. Am J OB/GYN, 1984. (2)Mechanisms of testosterone deficiency-related endothelial dysfunction. Antonopoulous AS and Antoniades C. Hellenic J Cardiol. 2018 Jun 8. pii:@1109-9666(18)30168-4. (3)Abraham Morgantaler et al., Testosterone therapy and cardiovascular Risk: Advanc